Ligand Pharmaceuticals (LGND) EBIT Margin Growth (5y) (2015 - 2026)

Ligand Pharmaceuticals (LGND) EBIT Margin Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Ligand Pharmaceuticals 5.87 Bn 4.51 Bn 60.48 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -4,452.00
Mar 31, 2026 2,346.00
Dec 31, 2025 -947.00
Sep 30, 2025 3,862.00
Jun 30, 2025 59.00
Mar 31, 2025 -9,131.00
Dec 31, 2024 1,519.00
Sep 30, 2024 2,686.00
Jun 30, 2024 -2,946.00
Mar 31, 2024 -189,115.00
Dec 31, 2023 -6,758.00
Sep 30, 2023 -4,180.00
Jun 30, 2023 -8,546.00
Mar 31, 2023 -3,366.00
Dec 31, 2022 -8,747.00
Sep 30, 2022 -1,528.00
Jun 30, 2022 283.00
Mar 31, 2022 -1,235.00
Dec 31, 2021 1,613.00
Sep 30, 2021 103.00